# Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer

> **NCT03104439** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 84 (actual)

## Conditions studied

- Microsatellite Stable Colorectal Cancer
- Pancreatic Cancer
- MSI High Colorectal Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT03104439
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-05-10
- **Primary completion:** 2027-01
- **Final completion:** 2027-04
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2026-01-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03104439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03104439, "Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03104439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*